Medicare AdvantageCoverageMedium impact
MA08.125d, Lurbinectedin (Zepzelca®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jun 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated the medical necessity criteria for lurbinectedin (Zepzelca®), a cancer medication used primarily in oncology. The billing team needs to review and understand the new criteria to ensure proper coverage determination and avoid claim denials.
Action Required
Before June 1, 2026: Billing team and providers must review the updated medical necessity criteria for lurbinectedin (Zepzelca®) at the source URL. Update prior authorization processes and documentation requirements in billing system to align with new criteria. Ensure oncology staff are aware of new requirements to prevent coverage denials.